Prudential plc, a life and health insurance and asset management company, disclosed transactions by its managerial personnel

UBS Group AG has crossed the 5% voting rights threshold in Prudential Public Limited Company (PUK), according to a recent SEC filing. The bank now holds 5.01% of voting rights through shares and 0.11% through financial instruments, totaling 5.12% as of September 11, 2026.

Prudential Public reported a 13% increase in new-business profit for H1, with bancassurance contributing 42%. Agency profit rose 5%, and health profit grew 15%. China faced regulatory challenges, while Malaysia and Hong Kong showed strong growth. The company is investing in India and reaffirmed its 2026 and 2027 targets. Prudential's shareholder capital ratio is 268%.

India’s CCI cleared Prudential Corporation Holdings’ plan to buy a 75% stake in Bharti Life Insurance Company Ltd. The deal follows Prudential plc’s May announcement to pay Rs 3,500 crore (about $389m) for the majority stake. Prudential said it will adjust its existing ICICI Prudential holdings to meet rules and may seek distribution deals with Bharti Airtel and 360 ONE.

SFL Corporation (NYSE: SFL) announced plans to acquire three vessels: two 8,800 TEU container vessels and one 93,000 cbm dual-fuel ammonia carrier. The acquisitions, costing approximately $333 million, include long-term charters with options for extension and purchase. According to the company, these charters will add significant revenue.

Cerebras Systems (CBRS) shares rose 10% and Oracle (ORCL) gained 4% on Oct. 27 after Oracle announced plans to offer Cerebras' AI inference on its cloud starting in 2027. The deal aims to provide customers with more AI chip options. Analysts estimate Cerebras' 2027 revenue at $2.95 billion, though no deal value was disclosed. Cerebras trades at roughly half its average forward price/sales multiple since its IPO.

ProKidney (NASDAQ:PROK) expects Phase III readout for rilparencel in Q2 2027, with enrollment surpassing 500. The therapy showed a 78% slower annual eGFR decline in Phase II. ProKidney aims to complement existing CKD treatments, with manufacturing efficiency improvements planned. Safety data aligns with prior trials, focusing on kidney biopsy-related events.